Confirmation of TEV Bead Activity with MBP-ENLYFQS-GFP (74.6 kD) test substrate. Two solutions were prepared; one with and one without the addition of TEV beads. After the beads are collected with a magnet; the sample solutions were run on SDS-PAGE and stained with Coomassie. Lane 1 shows the solution without TEV beads with a band at 74.6 kD. Lane 2 is the solution with active beads which shows two prominent bands at 47 and 28 kD (corresponding to MBP and GFP; respectively).

Cat. #160854

TEV HALO Magnetic Nanoparticles

Cat. #: 160854

Availability: 10-12 weeks

Application: Cleavage of affinity tags Identification of TEV sites in proteins Activation/inactivation of engineered proteins

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Enquire or request a quote

Contributor

Institute: East Carolina University

Tool Details

Handling

Application Details

References

Tool Details

*FOR RESEARCH USE ONLY

Tool name: TEV HALO Magnetic Nanoparticles
Description: Tobacco Etch Virus protease (TEVp)-labelled superparamagnetic nanoparticles for use in protein purification. TEVp removal is not necessary via column chromatography
Application: Cleavage of affinity tags Identification of TEV sites in proteins Activation/inactivation of engineered proteins
Additional notes: Please note this tool requires a magnet for bead separation (not included)

Handling

Storage conditions: 4° C (do not freeze)

Application Details

Application: Cleavage of affinity tags Identification of TEV sites in proteins Activation/inactivation of engineered proteins
Application notes: Please note this tool requires a magnet for bead separation (not included)

References

Norris, Jessica L et al. âCovalent and non-covalent strategies for the immobilization of Tobacco Etch Virus protease (TEVp) on superparamagnetic nanoparticles.â Journal of biotechnology vol. 322 (2020): 1-9. doi:10.1016/j.jbiotec.2020.06.021